Literature DB >> 19909895

Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline.

Jerry M Zuckerman1, Fozia Qamar, Bartholomew R Bono.   

Abstract

The advanced macrolides, azithromycin and clarithromycin, and the ketolide, telithromycin, are structural analogs of erythromycin. They have several distinct advantages when compared with erythromycin, including enhanced spectrum of activity, more favorable pharmacokinetics and pharmacodynamics, once-daily administration, and improved tolerability. Clarithromycin and azithromycin are used extensively for the treatment of respiratory tract infections, sexually transmitted diseases, and Helicobacter pylori-associated peptic ulcer disease. Telithromycin is approved for the treatment of community-acquired pneumonia. Severe hepatotoxicity has been reported with the use of telithromycin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19909895     DOI: 10.1016/j.idc.2009.06.013

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  24 in total

1.  Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2.

Authors:  G Eichenbaum; M K Pugsley; D J Gallacher; R Towart; G McIntyre; U Shukla; J M Davenport; H R Lu; J Rohrbacher; V Hillsamer
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

2.  Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1.

Authors:  Tomoki Maekawa; Hikaru Tamura; Hisanori Domon; Takumi Hiyoshi; Toshihito Isono; Daisuke Yonezawa; Naoki Hayashi; Naoki Takahashi; Koichi Tabeta; Takeyasu Maeda; Masataka Oda; Athanasios Ziogas; Vasileia Ismini Alexaki; Triantafyllos Chavakis; Yutaka Terao; George Hajishengallis
Journal:  JCI Insight       Date:  2020-08-06

Review 3.  Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.

Authors:  P M Bartold; A H du Bois; S Gannon; D R Haynes; R S Hirsch
Journal:  Inflammopharmacology       Date:  2013-02-28       Impact factor: 4.473

4.  A comparison of in vitro ADME properties and pharmacokinetics of azithromycin and selected 15-membered ring macrolides in rodents.

Authors:  Astrid Milić; Vlatka Bencetić Mihaljević; Jovica Ralić; Ana Bokulić; Danijela Nožinić; Branka Tavčar; Boris Mildner; Vesna Munić; Ivica Malnar; Jasna Padovan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-10-10       Impact factor: 2.441

5.  In Vitro Resistance Selection in Shigella flexneri by Azithromycin, Ceftriaxone, Ciprofloxacin, Levofloxacin, and Moxifloxacin.

Authors:  George P Allen; Kayla A Harris
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

6.  Investigating the barriers to bioavailability of macrolide antibiotics in the rat.

Authors:  Jasna Padovan; Jovica Ralić; Vatroslav Letfus; Astrid Milić; Vlatka Bencetić Mihaljević
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-11-24       Impact factor: 2.441

7.  Reticence to prescribe: utilization of expedited partner therapy among obstetrics providers in Arizona.

Authors:  M M Taylor; M G Collier; M M Winscott; T Mickey; B England
Journal:  Int J STD AIDS       Date:  2011-07-08       Impact factor: 1.359

8.  Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas.

Authors:  Trisha M Parekh; Mukaila Raji; Yu-Li Lin; Alai Tan; Yong-Fang Kuo; James S Goodwin
Journal:  JAMA Intern Med       Date:  2014-10       Impact factor: 21.873

Review 9.  Prescribing azithromycin.

Authors:  Brendan J McMullan; Mona Mostaghim
Journal:  Aust Prescr       Date:  2015-06-01

10.  Management of Acute Diarrheal Illness During Deployment: A Deployment Health Guideline and Expert Panel Report.

Authors:  Mark S Riddle; Gregory J Martin; Clinton K Murray; Timothy H Burgess; Patrick Connor; James D Mancuso; Elizabeth R Schnaubelt; Timothy P Ballard; Jamie Fraser; David R Tribble
Journal:  Mil Med       Date:  2017-09       Impact factor: 1.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.